Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Judith Balmaña

Showing results (11-20 of 194) with videos related to

Pageof 20
Sort By:
Cancer Discovery|May 16, 2012
Stumbling blocks on the path to personalized medicine in breast cancer: the case of PARP inhibitors for BRCA1/2-associated cancersJudith Balmaña, Susan M Domchek, Andrew Tutt, et al.
Statistics in Medicine|October 24, 2007
Data reduction for prediction: a case study on robust coding of age and family history for the risk of having a genetic mutationEwout W Steyerberg, Judith Balmaña, David H Stockwell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2017
Reply to R.L. Nussbaum et al and J.S. Dolinsky et alJudith Balmaña, Katherine Nathanson, Kenneth Offit, et al.
Medicina Clinica|March 17, 2020
Genetic counsellors in a multidisciplinary model of clinical genetics and hereditary cancerAdrià López-Fernández, Clara Serra-Juhé, Judith Balmaña, et al.
Breast Cancer Research and Treatment|August 21, 2008
The variants BRCA1 IVS6-1G>A and BRCA2 IVS15+1G>A lead to aberrant splicing of the transcriptsSara Gutiérrez-Enríquez, Verònica Coderch, Miriam Masas, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 7, 2022
Current Systemic Treatments for the Hereditary Cancer Syndromes: Drug Development in Light of Genomic DefectsElshad Hasanov, Isabel Pimentel, Mara Cruellas, et al.
Gynecologic Oncology|August 6, 2013
Mutation analysis of the BCCIP gene for breast cancer susceptibility in breast/ovarian cancer familiesSandra Bonache, Sara Gutierrez-Enriquez, Anna Tenés, et al.
Breast Cancer Research and Treatment|July 23, 2014
Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation statusAleix Prat, Cristina Cruz, Katherine A Hoadley, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 19, 2008
Phenotype comparison of MLH1 and MSH2 mutation carriers in a cohort of 1,914 individuals undergoing clinical genetic testing in the United StatesFay Kastrinos, Elena M Stoffel, Judith Balmaña, et al.
European Journal of Medical Genetics|October 4, 2021
Overview of hereditary breast and ovarian cancer (HBOC) guidelines across EuropeDavid Humberto Marmolejo, Mark Yu Zheng Wong, Svetlana Bajalica-Lagercrantz, et al.
Pageof 20

Showing results (11-20 of 194) with videos related to

Sort By:
Pageof 20
Cancer Discovery|May 16, 2012
Stumbling blocks on the path to personalized medicine in breast cancer: the case of PARP inhibitors for BRCA1/2-associated cancersJudith Balmaña, Susan M Domchek, Andrew Tutt, et al.
Statistics in Medicine|October 24, 2007
Data reduction for prediction: a case study on robust coding of age and family history for the risk of having a genetic mutationEwout W Steyerberg, Judith Balmaña, David H Stockwell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2017
Reply to R.L. Nussbaum et al and J.S. Dolinsky et alJudith Balmaña, Katherine Nathanson, Kenneth Offit, et al.
Medicina Clinica|March 17, 2020
Genetic counsellors in a multidisciplinary model of clinical genetics and hereditary cancerAdrià López-Fernández, Clara Serra-Juhé, Judith Balmaña, et al.
Breast Cancer Research and Treatment|August 21, 2008
The variants BRCA1 IVS6-1G>A and BRCA2 IVS15+1G>A lead to aberrant splicing of the transcriptsSara Gutiérrez-Enríquez, Verònica Coderch, Miriam Masas, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 7, 2022
Current Systemic Treatments for the Hereditary Cancer Syndromes: Drug Development in Light of Genomic DefectsElshad Hasanov, Isabel Pimentel, Mara Cruellas, et al.
Gynecologic Oncology|August 6, 2013
Mutation analysis of the BCCIP gene for breast cancer susceptibility in breast/ovarian cancer familiesSandra Bonache, Sara Gutierrez-Enriquez, Anna Tenés, et al.
Breast Cancer Research and Treatment|July 23, 2014
Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation statusAleix Prat, Cristina Cruz, Katherine A Hoadley, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 19, 2008
Phenotype comparison of MLH1 and MSH2 mutation carriers in a cohort of 1,914 individuals undergoing clinical genetic testing in the United StatesFay Kastrinos, Elena M Stoffel, Judith Balmaña, et al.
European Journal of Medical Genetics|October 4, 2021
Overview of hereditary breast and ovarian cancer (HBOC) guidelines across EuropeDavid Humberto Marmolejo, Mark Yu Zheng Wong, Svetlana Bajalica-Lagercrantz, et al.
Pageof 20